News

In this discussion, Brian Coffman, Ph.D., Director of the Clinical Neurophysiology Research Laboratory at the UPMC Western Psychiatric Hospital and Director of Research at UPMC Brain Mapping Center, explores how cannabis-associated psychosis may differ biologically from schizophrenia and what these insights mean for patients and clinicians.

 Sebastian Kaulitzki-stock@adobe.com

The phase 3 trial will evaluate the efficacy of pemvidutide, a dual glucagon/GLP-1 receptor agonist, in metabolic dysfunction-associated steatohepatitis patients with moderate to advanced fibrosis, using an AI tool to standardize liver biopsy assessment.

Sherry Young-stock@adobe.com

In June, the FDA's Vaccines and Related Biological Products Advisory Committee voted 9-0 in favor of Moderna’s mFlusiva, saying the benefits outweigh its risks for the prevention of influenza in adults older than 50.